When I first stepped into the ophthalmology ward at Hainan Eye Hospital in Boao, I did not expect to be deeply moved by a single moment. But there it was: an elderly woman from Inner Mongolia, nearly 70 years old, whose world had been reduced to shadows for three long years. When the surgical team gently removed the gauze from her eyes, she did something that caught everyone off guard—she pulled the surgeon’s hand close to her face, gazed at his features as if seeing him for the very first time, and whispered, “I can see your face. Thank you from the bottom of my heart.”
She was not looking at some cutting-edge gadget or a revolutionary drug. She was looking at something more precious: a clear, steady cornea that a synthetic membrane called EndoArt had given back to her.
What Is Corneal Transplantation, and Why Does It Remain So Challenging?
For decades, the standard solution has been corneal transplantation: replacing the diseased cornea with healthy tissue from a human donor. But here lies the difficulty. Around the world, donor corneas are in desperately short supply. In China alone, an estimated 4 million people suffer from corneal blindness, with more than 100,000 new cases added each year. The most distressing part? Ninety percent of these patients are forced to wait indefinitely—sometimes for years—because the demand for donor tissue far outstrips its availability.
And even when a donor cornea becomes available, the journey is far from over. The immune system, which serves as our body’s vigilant sentinel, often recognizes the transplanted tissue as foreign and launches an attack. Graft rejection is the most common cause of corneal transplant failure. For patients undergoing conventional corneal transplantation for the first time with no complicating factors, two-year survival rates exceed 90%. But for high-risk patients—those with previous graft failure, ocular trauma, glaucoma surgery, or severe corneal vascularization—those survival rates plummet to between 35% and 70%.
What Is EndoArt, and How Is It Different?
The device itself is remarkably elegant. It is a flexible, 50-micrometer-thin artificial endothelial layer made from a transparent, biocompatible synthetic material—a copolymer of hydroxyethyl methacrylate and methyl methacrylate. Imagine a contact lens, but instead of sitting on the surface of the eye, it is implanted inside the anterior chamber, positioned carefully against the posterior surface of the cornea.
What does it do? The native corneal endothelium acts as a pump, actively removing fluid from the corneal stroma to maintain clarity. EndoArt does not pump—at least not in the active biological sense. Instead, it functions as a physical barrier, preventing fluid from migrating from the aqueous humor into the corneal tissue. By sealing the leak, it allows the cornea to dry out, return to its normal thickness, and regain transparency.
The most striking difference from traditional transplantation is that EndoArt eliminates immune rejection. Because the device is synthetic and non-biological, the immune system has nothing to recognize as foreign. There is no need for long-term immunosuppressive eye drops. There is no risk of rejection creeping up months or years after surgery. In a systematic review of clinical outcomes, no immune responses were reported across multiple studies.
For patients who have already lost one graft to rejection—or two, or three—this is not merely an incremental improvement. It is a lifeline.
Who Is This For, and Which Hospital Is Leading the Way?
EndoArt is not intended for every patient with corneal disease. It is designed for a specific, often neglected group: those with chronic corneal edema that has failed to respond to conventional treatment, or those at such high risk of graft rejection that a traditional corneal transplant is unlikely to succeed.
Who fits this description? Consider patients who have undergone multiple failed corneal transplants—clinical data show that 82% of EndoArt recipients have had at least one previous corneal transplant, and 39% have had three or more. Consider patients with pre-existing glaucoma who have had filtration surgery or drainage devices—83% of EndoArt recipients in one reported series had such comorbidities. Consider those with severe ocular burns, multiple intraocular surgeries, or corneal vascularization that makes any biological transplant a high-risk proposition.
For these individuals, EndoArt is not just an option. It is often the only remaining option.
The hospital spearheading this innovation in China is Hainan (Boao) International Eye Hospital, located within the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province. Established in 2018, this hospital was the first super-specialty ophthalmology platform launched in the Lecheng Pilot Zone. It is operated under the leadership of Professor Chen Wei, Vice Dean of the Eye Hospital of Wenzhou Medical University, one of China’s most accomplished corneal surgeons with over 4,000 innovative corneal transplant procedures to his name.
What makes Boao special is the national policy that allows qualified medical institutions within the Pilot Zone to import cutting-edge medical devices and pharmaceuticals that have been approved overseas but are not yet commercially available in mainland China. This “pilot first” policy has enabled Hainan Eye Hospital to bring EndoArt to Chinese patients years ahead of the conventional regulatory timeline.
As of the latest data, Hainan Eye Hospital has successfully introduced 42 ophthalmology-related特许medical devices under the Pilot Zone’s special policies, completing more than 2,000 procedures and creating 36 national firsts.
And here is something I find deeply reassuring as a medical tourism professional: the patients who have received EndoArt at Hainan Eye Hospital have experienced tangible, measurable improvement. In a clinical study published in the Chinese Journal of Optometry & Ophthalmology, all four patients who underwent EndoArt implantation at the hospital achieved stable membrane attachment with no device-related adverse events. Central corneal thickness decreased significantly in every case, corneal edema resolved, and patients reported marked relief from ocular pain.
A Story Worth Telling
Mrs. Tian’s eyes first started troubling her three years ago. At first, it felt like sand trapped under her eyelids—mild, easily dismissed. But soon, her vision deteriorated rapidly. “It was like looking through frosted glass,” she recalled. The diagnosis was devastating: due to multiple prior glaucoma and cataract surgeries, her iris had adhered to the cornea, damaging the endothelial layer beyond repair.
Her husband, Yang Dong, took her to the best eye hospitals across China. The answer was always the same: she needed a corneal transplant, and she would have to wait—perhaps for years—for a donor. Then they heard about Hainan Eye Hospital in Boao, where EndoArt was available under the Pilot Zone’s special policies. They traveled nearly 2,400 kilometers from Inner Mongolia to the southern coast of Hainan.
On June 26, 2023, after just 40 minutes of surgery, Mrs. Tian emerged with something she had nearly lost: hope. The surgical team told her, “The surgery was very successful.” A few days later, as she prepared to leave the hospital, she said something that still echoes in my mind: “I want to come back to Hainan someday, just to see the sea for myself”.
What moves me about Mrs. Tian's story is not just her restored vision. It is the acknowledgment that vision is not merely a biological function. It is connection—to faces we love, to the horizon, to a world we once thought we had lost.
What Does the Evidence Actually Say?
In the medical tourism industry, we encounter no shortage of bold claims. So I made it a point to examine the scientific literature on EndoArt before I felt comfortable recommending it to my patients. The results, I must say, are compelling.
Across multiple clinical studies, EndoArt has been shown to reduce central corneal thickness by 24% at one year and 28% at three years, with 86% of treated eyes showing significant thickness reduction. Visual acuity improves substantially, with mean best-corrected visual acuity changing from 1.61 logMAR to 1.07 logMAR (p < 0.001). Eighty-one percent of patients achieve improved corneal clarity, and 92% report significant reduction in ocular pain.
The most commonly cited complication is partial device detachment requiring a rebubbling procedure. Across the published literature, the pooled rebubbling rate is approximately 60%. I want to be transparent about this: rebubbling is a relatively minor procedure that involves injecting a small gas bubble into the anterior chamber to reposition the membrane. It is not a catastrophic event, and it does not compromise the long-term outcome. Importantly, the device is easily repositionable and even removable if necessary.
What the literature does not show is any evidence of immune rejection, device degradation, or pathological thinning of the cornea over time.
My Final Thoughts
As someone who works at the intersection of medical tourism and life-changing surgical care, I have learned to distinguish between incremental innovations and genuine breakthroughs. EndoArt, in my judgment, belongs in the latter category. It does not solve every problem in corneal transplantation—the rebubbling rate needs to be improved, and it is best suited as salvage therapy for complex cases rather than first-line treatment. But for the patient who has already endured multiple transplant failures, for the patient with severe glaucoma who cannot risk another biological graft, for the patient who has been told “there is nothing more we can do”—EndoArt offers something that synthetic medicine at its best can offer: a second chance.
And that brings me back to Mrs. Tian, standing in the bright sunlight of a Boao afternoon, touching her husband’s hand and describing his face to him as if she were memorizing it for the first time. Some innovations are measured in research papers, FDA designations, and clinical endpoints. But some must be measured differently—in the moments when darkness becomes light, and a human being dares to hope again.
